Coskun Benlidayi, İ. 2021. What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.. International journal of rheumatic diseases , vol.24 , 724-727.

Coskun Benlidayi, İ., (2021). What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.. International journal of rheumatic diseases , vol.24, 724-727.

Coskun Benlidayi, İLKE. "What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.," International journal of rheumatic diseases , vol.24, 724-727, 2021

Coskun Benlidayi, İLKE C. . "What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.." International journal of rheumatic diseases , vol.24, pp.724-727, 2021

Coskun Benlidayi, İ. (2021) . "What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.." International journal of rheumatic diseases , vol.24, pp.724-727.

@article{article, author={İLKE COŞKUN BENLİDAYI}, title={What are the benefits and harms of anti-cytokine targeted therapies for adults with anti-neutrophil cytoplasmic antibody-associated vasculitis? - A Cochrane Review summary with commentary.}, journal={International journal of rheumatic diseases}, year=2021, pages={724-727} }